Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supreme Court’s Copaxone Ruling Could Increase Expert Witness Testimony

This article was originally published in The Pink Sheet Daily

Executive Summary

High court rules Federal Circuit should have granted deference to district court’s decision on meaning of Copaxone patent claim; Federal Circuit must now reconsider its finding that the patent is invalid.


Related Content

Generic Relabeling Speed Could Get Supreme Court Review
Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts